BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

AVEO Oncology Selects Ficlatuzumab Dose for Phase 3 FIERCE-HN Trial in Head and Neck Cancer

– Global enrollment continues in the Phase 3 registrational studyfollowing the planned first interim analysis for patients with HPV-negati...

February 24, 2026 | News

ImmunityBio Partners With Accord Healthcare To Expand ANKTIVA Access Across Europe

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced a partnership with Accord Healthcare to provide access to ANKTI...

February 23, 2026 | News

ANKTIVA Plus BCG Secures European Commission Authorization As First Immunotherapy For BCG Unresponsive NMIBC

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive blad...

February 20, 2026 | News

Telix Submits European Marketing Application For TLX101 Px To Expand Glioma PET Imaging Access

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe ...

February 19, 2026 | News

Bio Techne Corporation Announces CE IVD Marking For Ella Benchtop Immunoassay Platform In European Union

Ella benchtop instrument is now CE-IVD marked and available for sale in the EU Enables diagnostic assay developers to leverage a simplified platform tha...

February 18, 2026 | News

Eli Lilly And Company Reports Statistically Significant Event Free Survival Benefit With Selpercatinib In Early Stage RET Fusion Positive NSCLC

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or deat...

February 18, 2026 | News

Innovent Advances IBI354 Into Pivotal Phase Three Trial For HER2 Positive Advanced Breast Cancer

Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medi...

February 16, 2026 | News

Jyong Biotech Strengthens Preventive Medicine Position With Positive Phase II Data And Asian Expansion

Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modul...

February 16, 2026 | News

HanchorBio Secures FDA Orphan Drug Designation For HCB101 In Gastric Cancer

First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnolog...

February 16, 2026 | News

Alphamab Oncology Advances JSKN003 Into Phase III Trial For HER2 Positive Advanced Colorectal Cancer

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005...

February 16, 2026 | News

SOPHiA GENETICS Expands US Footprint With Two Major Health System Partnerships

SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, announced the addition of two of the largest U.S. healthcare systems ...

February 12, 2026 | News

Kirin Holdings And Immunosens Launch Joint Development Of Immune Self Testing Service

Kirin Holdings Company, Limited (Kirin Holdings) and Immunosens Co., Ltd. (Immunosens) have begun the joint development of a unique “Self-Testing Ser...

February 11, 2026 | News

Eurofins Viracor BioPharma Expands GLP And GCP Bioanalytical Testing Capabilities

Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers...

February 11, 2026 | News

Innovent Biologics And Eli Lilly Expand Oncology And Immunology Alliance With Global Development Model

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

February 10, 2026 | News

Stay Connected